

FORM PTO-1390
(REV. 7-2004)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTORNEY'S DOCKET NUMBER
11183-003-999

U.S. APPLICATION NO. (if known, see 37CFR 1.5)

10/524134

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371**

INTERNATIONAL APPLICATION NO. PCT/US03/25399	INTERNATIONAL FILING DATE August 14, 2003	PRIORITY DATE CLAIMED August 14, 2002
TITLE OF INVENTION FcGAMMA RIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF		
APPLICANT(S) FOR DO/EO/US Scott Koenig and Maria Concetta Veri		

Applicant herewith submits to the United States Designated/ Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. The U.S. has been elected (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US), but a courtesy copy is attached hereto
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. is attached hereto.
 - b. has been previously submitted under 35 U.S.C. 154(d)(4).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration (executed) of the inventor(s) (35 U.S.C. 371(c)(4)).
10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 20. below concern document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A preliminary amendment.
14. An Application Data Sheet under 37 CFR 1.76.
15. A substitute amendment.
16. A power of attorney by assignee and/or change of address letter.
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13^{ter} 2 and 37 CFR 1.821- 1.825.
18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).
19. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).
20. Other items or information: copy of International Publication No. WO 2004/016750 A2, which is the publication of PCT/US03/25399; and copy of International Search Report; and copy of International Application PCT/US03/25399 as filed

US APPLICATION NO. (if known, see 37 CFR 1.5) 10/52413	INTERNATIONAL APPLICATION NO. PCT/US03/25399	ATTORNEY'S DOCKET NUMBER 11183-003-999		
21. The following fees are submitted:		CALCULATIONS PTO USE ONLY		
BASIC NATIONAL FEE (37 CFR 1.492 (A) (1) - (5)):				
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....		\$1,110.00		
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....		\$950.00		
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....		\$790.00		
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4).....		\$750.00		
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4).....		\$100.00		
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 750.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).		\$.00		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE X	
Total Claims	110	90	\$50.00	4500.00
Independent Claims	28	25	\$200.00	= 5000.00
<input checked="" type="checkbox"/> MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ 360.00	-	360.00
TOTAL OF ABOVE CALCULATIONS =		= \$ 10,610.00		
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		- \$ 5305.00		
SUBTOTAL =		= \$ 5305.00		
Processing fee of \$130.00 for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				
TOTAL NATIONAL FEE		= \$ 5305.00		
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). x \$40.00 per property		\$ 0.00		
TOTAL FEES ENCLOSED		= \$ 5305.00		
		Amount to be refunded:		
		charged:	5305.00	
a. <input type="checkbox"/> A check in the amount of \$0.00 to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge Deposit Account No. 50-3013 to cover the above fees. A copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-3013. A copy of this sheet is enclosed.				
Note: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the International Application to pending status.				
22. <input type="checkbox"/> Other instructions				
23. <input checked="" type="checkbox"/> All correspondence for this application should be mailed to JONES DAY 20583				
24. <input type="checkbox"/> All telephone inquiries should be made to				
Margaret B. Brivanlou		By: Margaret B. Brivanlou T.C. Tsoi 40,258 40,922 REG. NO.	February 11, 2005 DATE	
SIGNATURE				

PATENT IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: KOENIG et al. Confirmation No. To be assigned

Serial No.: To be assigned; National Stage Art Unit: To be assigned
Application of International
Application No. PCT/US03/25399
filed August 14, 2003

Filed: On even date herewith Examiner: To be assigned

For: Fc GAMMA RIIB SPECIFIC Attorney Docket No. 11183-003-999
ANTIBODIES AND METHODS OF (CAM: 505421-999002)
USE THEREOF

TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In connection with the filing of the above-identified application, transmitted herewith are the following documents:

1. Transmittal Letter to the United States Designated/Elected Office (Form PTO-1390) (in duplicate);
2. Copy of the International Application as filed;
3. Copy of the International Publication WO 2004/016750 A2;
4. Copy of the International Search Report;
5. Transmittal of Declaration accompanied by Executed Declaration;
6. Transmittal of Sequence Listing under 37 C.F.R. § 1.821;
7. Power of Attorney by Assignee and Exclusion of Inventor(s) under 37 C.F.R. § 3.71 with Statement under 37 C.F.R. § 3.73(b) executed by Michael Richman on behalf of MacroGenics, Inc. Mr. Richman is authorized to act on behalf of MacroGenics, Inc.
8. Copies of Assignment of the above-identified application to MacroGenics, Inc. which is concurrently submitted to the Assignment Recordation services for Recordation; and
9. Transmittal of Formal Drawings and 37 C.F.R. §§ 1.84 and 1.85 accompanied by Figures 1-16 (29 sheets).

10/524134

DT05 rec'd PCT/PTO 11 FEB 2005

This application is a National Stage Application of International Application No. PCT/US03/25399, filed August 14, 2003, which claims the benefit of U.S. Provisional Application No. 60/403,266 filed August 14, 2002.

Respectfully submitted,

By: *W.C. Tsang*
T.C. TSANG

40,258

Date: February 11, 2005

Margaret B. Brivanlou

40,922

Margaret B. Brivanlou

Reg. No.

JONES DAY

222 East 41st Street

New York, New York 10017

Telephone Number: 212-326-3939

Fax Nos.: (212) 755-7306

Enclosures

Express Mail No.: EV 452 774 625 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: KOENIG et al.

Confirmation No. To be assigned

Serial No.: To be assigned; National Stage
 Application of International
 Application No. PCT/US03/25399
 filed August 14, 2003

Art Unit: To be assigned

Filed: On even date herewith

Examiner: To be assigned

For: FC GAMMA RIIB SPECIFIC
 ANTIBODIES AND METHODS OF
 USE THEREOF

Attorney Docket No. 11183-003-999
 (CAM: 505421-999002)

TRANSMITTAL OF FORMAL DRAWINGS UNDER 37 C.F.R. §§1.84 AND 1.85

Commissioner For Patents
 P. O. Box 1450
 Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith twenty-nine (29) sheets of formal drawings of Figures 1(A-D), 2, 3, 4, 5(A-C), 6(A-B), 7(A-C), 8(A-C), 9(A-D), 10(A-G), 11(A-P), 12(A-B), 13(A-C), 14(A-T), 15(A-B), and 16 (A-C). The formal drawings are submitted in compliance with the requirements for formal drawings enumerated in 37 C.F.R. §§1.84 and 1.85.

No fee is believed due; however, should the Patent and Trademark Office determine otherwise, please charge the required fee to Deposit Account No. 50-3013.

Applicants respectfully request entry of the corrected formal drawings.

Respectfully submitted,


 40,258

Margaret B. Brivanlou 40,922
 Margaret B. Brivanlou (Reg. No.)

JONES DAY
 222 East 41st Street
 New York, New York 10017-6702
 (212) 326-3939

Enclosures

10/524 134

DT05 2'd PCT/PTO 11 FEB 2005

Express Mail No. EV 452 774 625 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: KOENIG et al.

Confirmation No.: To be assigned

Serial No.: To be Assigned (U.S. National
Stage of PCT/US03/25399)

Art Unit: To be assigned

Filed: On Even Date Herewith

Examiner: To be assigned

For: Fc GAMMA RIIB SPECIFIC
ANTIBODIES AND METHODS
OF USE THEREOF

Attorney Docket No: 11183-003-999
(CAM:) (505421-999002)

**TRANSMITTAL OF DECLARATION FOR
NON-PROVISIONAL PATENT APPLICATION**


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith, in connection with the above-identified application, a Declaration for Non-Provisional Patent Application ("Declaration") executed by Scott Koenig and Maria Concetta Veri, as inventors of the above-identified application.

No fee is believed due with the filing of this Declaration. Should any fee be due, please charge the required fee to the Jones Day Deposit Account No. 503013.

Respectfully submitted,

By: 
T. C. Tsang

Date: February 11, 2005

Margaret B. Brivanlou 40,922
Margaret B. Brivanlou (Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939